Loss of heterozygosity (LOH or allele loss) has become established as a marker for tumour suppressor gene loss at several loci in a wide range of cancers. Certain sites, identified by LOH studies, may contain tumour suppressor genes involved in more than one type of malignancy. The paradigm for this is the p53 tumour suppressor gene for which LOH, often with mutation of the remaining allele, has been described in many types of cancer. While the p53 gene has been extensively investigated, other loci involved in colorectal cancer such as 5q21, which contains the adenomatous polyposis coli (APC) and mutated in colon cancer (MCC) genes, and 18q21.3 bearing the deleted in colon cancer (DCC) locus have been less well documented in other cancer types.
5q21 (APC/MCC)
There is strong evidence for the involvement of the 5q21 locus in colorectal cancer. Loss of heterozygosity from 5q21 has been identified in over 40% of sporadic colorectal cancers (Solomon et al., 1987; Vogelstein et al., 1988; Ashton-Rickart et al., 1989; and may be an early event in colorectal neoplasia since 5q21 LOH has been demonstrated in small colonic adenomas (Vogelstein et al., 1988) . Furthermore, somatic mutations have been identified within the APC and MCC genes in colorectal cancers Kinzler et al., 1991a) .
LOH from 5q21 has also been noted in 21-40% of non small cell lung cancers (Ashton-Rickart et al., 1991; D'Amico et al., 1992) , 80% of small cell lung cancers (D'Amico et al., 1992) and 77% of oesophageal cancers (Boynton et al., 1992) .
The function and interaction of MCC and APC remains speculative, but two functions, as a G protein and 'coiled coil', have attracted debate. The MCC gene, and to a lesser extent the APC gene, shares a short region of similarity with the m3 muscarinic acetylcholine receptor which mediates acetylcholine stimulation of phosphoinositide-specific phospholipase C via a G protein (Kinzler et al., 1991a; Bourne, 1991) . It is therefore possible that both APC & MCC products may operate on the same biochemical pathway reveal regions with strong coiled coil potential (Bourne, 1991) similar to nuclear lamin and intermediate filament proteins (Kinzler et al., 1991b (Bourne, 1991; Groden et al., 1991; Joslyn et al., 1991 (Weinberg, 1991 (Vogelstein et al., 1988; . Indeed, LOH from 18q may be a particular feature of gastrointestinal cancers: gastric cancer shows 61% LOH at the DCC locus (Uchino et al., 1992) and pancreatic cancers and pancreatic cell lines show loss of DCC expression (Hohne et al., 1992) . However, LOH from 18q has now been reported in up to 64% of osteosarcomas (Yamaguchi et al., 1992) , 60% of ovarian cancers (ChenevixTrench et al., 1992) , 33% of renal tumours (Bergerheim et al., 1989) and 11% of lung cancers (Yokota et al., 1987) . In sporadic breast cancer, reports of LOH at the DCC locus range from only I of 40 (2.5%) informative cancers (Sato et al., 1991) to 13/45 (27%) tumours with DCC allele loss or duplication (Devilee et al., 1991) . Less specific markers (OS4 at 18q21.3-qter) have shown 69% (11/34) allele loss (Cropp et al., 1990) , 14% allele loss (Merlo et al., 1992) , or 38% (17/45) allelic imbalance (Devilee et al., 1991) (Thompson et al., 1990a) were also snap frozen and stored at -70°C.
Nucleic acid extraction High molecular weight DNA was extracted from paired frozen tumour tissue and venous blood lymphocytes. Briefly, the tissues or cells were lysed with SDS, protein digested and removed by phenol/chloroform extraction then DNA precipitated using ethanol in the presence of salt. The DNA was redissolved in Tris/EDTA buffer and the concentration and purity determined by spectrophotometry at 260 nm and 280 nm (Thompson et al., 1990b) .
Total RNA was extracted using a modification of the lithium chloride/urea differential precipitation method (Thompson et al., 1990b) , which utilises ultrasonic disruption of DNA, then proteinase K treatment and phenol extraction to remove protein, followed by precipitation of the total RNA using alcohol. The RNA was redissolved in double autoclaved diethyl pyrocarbonate (DEPC) treated water, the quantity and purity of the RNA determined by spectrophotometry at 260 nm and 240 nm and the RNA stored in aliquots at -70°C.
Southern blot analyses DNA (5 rg) from each patient's blood and tumour was digested using an appropriate bacterial endonuclease, the pairs of blood (constitutional) and tumour DNA subjected to electrophoresis alongside digested lamda markers on a 0.8% agarose gel, the DNA fragments transferred by Southern blotting to hybond-N membrane (Amersham, UK) and fixed to the membrane by exposure to ultraviolet light.
The hybond nylon membrane was pre-hybridised in hybridisation buffer (5 x Denharts, 5 x SSC, 0.1% SDS, 10% dextran sulphate). To this 107 cpm ml-' 32p CTP probe, labelled using a random-prime DNA-labelling system (Boehringer Mannheim), was added and allowed to hybridise for 24 h. Excess probe was washed off the membrane using successive washes of 0.1% SDS and 1 x SSC and the DNA alleles detected by auto-radiography with Kodak XAR film at -70°C.
The probes used to examine the blood/tumour pairs (Table  I) (Table II) . Using five probes mapping to 5q21 (Table I) , 25 of the 32 patients examined were informative for at least one probe and seven (28%) exhibited unequivocal allele loss (Figure 1 ). At 18q21, 15 of the 26 patients were informative using the p15.65 and Saml.1 probes and 5 (31%) showed allele loss (Figure 2 ). At I7pI3, 31 of the 34 patients were informative and 22 (71%) had loss of heterozygosity. A more detailed comparison of the three regions ( Figure 3) shows that all 34 patients were informative at one or more of the three loci examined and ten patients were informative for all three regions. of the 22 tumours with allele loss were oestrogen receptor poor (less than 20 fmol mg protein-') but only three of nine tumours with retention of heterozygosity were oestrogen receptor poor. Four of the five tumours which expressed the truncated DCC mRNA of 11 kb were oestrogen receptor moderate or rich (greater than 20 fmol mg protein-').
Discussion
This study examined 34 untreated sporadic primary breast cancers for LOH at 5q21 and 18q21, and compared these events to LOH and mutation of the p53 gene. We have identified tumour allele losses at 5q21 (APC/MCC) in 28% of informative patients and at 18q21 (DCC) in 31% of patients compared with 71% LOH at 17pl3 (p53). Clearly LOH at 5q21 (APC/MCC) occurs in sporadic breast cancers as in other types of malignancy (Solomon et al., 1987; Vogelstein et al., 1988; Ashton-Rickart et al., 1989; Miki et al., 1991) , at a similar rate to non small cell lung cancer (Ashton-Rickart et al., 1991) . Detailed studies of 5q21 in sporadic colorectal cancer suggest that APC or MCC can be the targets for deletion, although either may be involved in individual tumours Kinzler et al., 1991b) . Detailed studies of 5q21 in breast cancer (including mutation analysis) would be required before there was conclusive evidence of APC or MCC involvement: there are other candidate genes within the region -Ter (a tyrosine kinase homologue to src), TBI (which has similarities to ADP/ATP carrier/translocation genes) SRP19 and TB2 (Kinzler et al., 1991b; D'Amico et al., 1992 the DCC locus (Devilee et al., 1991) . As previously noted, (Sato et al., 1991) there were no rearrangements of DCC in the 34 breast cancers studied here; a rare event even in colorectal cancer . However, LOH from 18q21 in breast cancer appears to be less common than for colorectal cancer (Vogelstein et al., 1988; , gastric cancer (Uchino et al., 1992) , ovarian cancer (Chenevix-Trench et al., 1992) or osteosarcoma (Yamaguchi et al., 1992) .
We present the first evidence for DCC gene mRNA expression in human breast cancer. As expected, brain tissue expressed DCC mRNA, but we were unable to demonstrate DCC mRNA expression in three breast cancer cell lines, as for most colorectal cancer cell lines in normal breast tissue, lymphoid (tonsil) tissue or colonic mucosa. While the absence of detectable DCC mRNA expression in some cancers may confer a growth advantage (Weinberg, 1991) , 14 cancers did express DCC mRNA and in five there was an additional, truncated DCC mRNA. These five tumours, which also had LOH at DCC, may contain mutations that create a potential 3" splice acceptor site . Such mutations could result in abnormal RNA processing to produce truly abnormal truncated mRNA or simply alternatively spliced DCC mRNA. To date, no protein product has been identified in these tumours (Vogelstein, personal communication) . Even in the presence of abnormal DCC transcription, translation to protein may be aberrant.
MCF-7 cells grown in vitro did not express detectable DCC mRNA; grown as a tumour xenograft, high levels of DCC mRNA were detected (Figure 4) . It is possible that DCC expression may be increased in cells subjected to contact inhibition in keeping with its suggested function as a cell adhesion molecule . However, at the DNA and protein levels we have little idea of DCC function or expression in these xenografts which grow slowly and rarely metastasise (Thompson et al., 1990a) . In addition, other mechanisms such as enhancer mediated silencing or gene methylation could account for DCC gene repression in vitro (Hohne et al., 1992) .
It has been suggested that there is a significant link in breast cancer between LOH from 18q21 and LOH from l7pl3 which bears the p53 locus (Cropp et al., 1990; Devilee et al., 1991) . We have previously documented p53 allele losses and mutations (Thompson et al., 1992 ) in a series of tumours which include those studied here at the DCC and APC/MCC loci. As the detailed data shows (Figure 3) , five tumours had LOH from 5q concurrently with 17p LOH, three tumours had LOH from both 18q and 17p and one tumour had LOH from all three loci. Thus, concurrent allele loss certainly occurs.
It is possible that the LOH observed in this study may be due to chance. However, the accumulation of genetic defects such as those demonstrated here, could confer a growth advantage on a cell and allow subsequent clonal expansion that makes further events at other crucial loci more likely and may be important in the development of breast cancer.
On the basis of the data presented here, we propose that further study of the APC/MCC genes and DCC locus in breast cancer, including structural analysis, merits consideration.
